Peer-reviewed veterinary case report
Biomarker levels in cats with heart muscle thickening and mitral
By Seo, Joonbum et al.·Published in Journal of veterinary internal medicine·2020·Royal Veterinary College, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Biomarker changes with systolic anterior motion of the mitral valve in cats with hypertrophic cardiomyopathy.
- Species:
- cat
Plain-English summary
A group of 140 cats with hypertrophic cardiomyopathy (HCM), a common heart condition, were studied to see how a specific heart issue called systolic anterior motion of the mitral valve (SAM) affected certain blood markers. The cats with both HCM and SAM had significantly higher levels of two important heart-related markers, NT-proBNP and cardiac troponin-I, compared to those with HCM but without SAM. This suggests that if your cat has HCM and shows signs of SAM, it may indicate more severe heart issues. Understanding these markers can help veterinarians better assess your cat's heart health.
People also search for: cat heart disease symptoms · hypertrophic cardiomyopathy in cats · NT-proBNP levels in cats
Abstract
BACKGROUND: N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I (cTnI) are biomarkers commonly evaluated in cats with suspected heart disease. Many cats with hypertrophic cardiomyopathy (HCM) have systolic anterior motion of the mitral valve (SAM), but its influence on circulating NT-proBNP or cTnI concentrations is currently unknown. HYPOTHESIS/OBJECTIVES: Cats with HCM and SAM (HCM) have higher NT-proBNP and cTnI concentrations than do cats with HCM but without SAM (HCM). ANIMALS: One hundred forty cats with HCM: 70 with SAM and 70 without SAM. METHODS: Retrospective case-to-case study. Cats were recruited if diagnosed with HCM by echocardiography and results were available for NT-proBNP or cTnI concentrations or both. Cats with SAM were matched to those without SAM for clinical presentation, left atrial (LA) size and left ventricular (LV) fractional shortening. RESULTS: A total of 119 NT-proBNP and 123 cTnI results were available. The HCMcats had higher median concentrations than did HCMcats for NT-proBNP (729 pmoL/L; interquartile range [IQR], 275-1467 versus 65 pmoL/L; IQR, 25-271; P < .001) and cTnI (0.27 ng/mL; IQR, 0.10-0.81 versus 0.07 ng/mL; IQR, 0.01-0.43; P = .002). In general linear models for both NT-proBNP and cTnI, the independent explanatory variables were SAM, congestive heart failure, maximal LV wall thickness, and LA size. CONCLUSIONS AND CLINICAL IMPORTANCE: For cats with HCM and equivalent LA size and LV systolic function, those with SAM had higher NT-proBNP and cTnI concentrations than did those without SAM. Presence of SAM should be considered when interpreting biomarker concentrations in cats with HCM.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32822105/